- How common, and when. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. doi:10.1111/dom.14551. Nausea affected 43.9 percent of participants on semaglutide 2.4 mg against 16.1 percent on placebo, was reported more frequently during dose escalation, and cumulative incidence plateaued after around week 20.
- Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336-347. doi:10.1111/dom.12824. Establishes that rates differ substantially by agent, dose and formulation, which is why this kit does not quote a single class wide figure.
- Managing it. Gorgojo-Martinez JJ, Mezquita-Raya P, Carretero-Gomez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145. doi:10.3390/jcm12010145. Expert consensus covering how to reach the maintenance dose, how to proceed if gastrointestinal effects appear during escalation, and practical measures for nausea, vomiting, diarrhoea and constipation. This is the source for eating slowly, stopping at comfortable fullness, smaller portions, limiting high fat meals and staying upright. These measures are recommended by consensus; they have not been tested against one another in trials.
- Prescribing information. [VERIFY REVISION DATE BEFORE EACH RELEASE] Novo Nordisk Inc. Wegovy (semaglutide) injection, for subcutaneous use: US prescribing information. Plainsboro, NJ: Novo Nordisk Inc. NDA 215256. Revised 02/2026 (label supplement s033); a further labelling revision dated 06/2026 is reflected in the manufacturer posted PI. Novo Nordisk Inc. Wegovy (semaglutide) tablets: US prescribing information. NDA 218316. Revised 01/2026 (label supplement s002). Eli Lilly and Company. Zepbound (tirzepatide) injection, for subcutaneous use: US prescribing information. Indianapolis, IN: Eli Lilly and Company. NDA 217806. 2026 revision (label supplement s042). All list nausea, vomiting, diarrhoea and constipation among common adverse reactions, and all carry dose escalation guidance intended to reduce gastrointestinal adverse reactions. The Zepbound label reports discontinuation due to gastrointestinal adverse reactions in 3.3 percent at 10 mg and 4.3 percent at 15 mg against 0.5 percent on placebo. These labels are revised frequently. Always read the current version for the product you were actually prescribed.
- Where this sits in care. World Health Organization. WHO guideline on the use of GLP-1 therapies for the treatment of obesity in adults. Geneva: WHO; December 2025. Positions these therapies within comprehensive care including diet, physical activity and professional support.
- Spreckley M, Ruggiero CF, Brown A. Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: lessons from bariatric surgery. Int J Obes. 2026;50:265-267. doi:10.1038/s41366-025-01952-w. Published online November 15, 2025. Sets out how little structured nutritional guidance accompanies these medications in practice.
- Ginger. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth. 2000;84(3):367-371. doi:10.1093/oxfordjournals.bja.a013442. And: Viljoen E, Visser J, Koen N, Musekiwa A. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutr J. 2014;13:20. doi:10.1186/1475-2891-13-20. Extrapolated evidence. Ginger has randomised evidence for postoperative and pregnancy related nausea. It has not been tested for GLP-1 related nausea. It appears in this kit because it is low risk and some women find it helps, not because it has been shown to work for this.
- Why it matters for staying on treatment. Gastrointestinal symptoms are the most consistently reported self reported reason for stopping GLP-1 therapy. See references 1 to 3 and the WHO guideline above.
- Hormonal context. No source is cited for a claim that menopause stage or cycle phase determines whether nausea is medication related, because this kit no longer makes that claim. Sex hormones and menstrual phase may influence gastrointestinal motility and symptom perception in some women, but the evidence is heterogeneous. This kit records the pattern rather than assuming a cause.
How to read this list. References 1 to 3 and 5 are the evidence base for what this kit tells you. Reference 4 is the label for your own medication and outranks everything here. Reference 7 is explicitly extrapolated from other settings and is labelled as such wherever it appears. Where evidence is absent, as in reference 9, this kit says so rather than filling the gap.
Clinical content reviewed by a PharmD. Sources cited above.